New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 20, 2012
11:08 EDTSYUT, DANOY, MJN, NSRGY, PFEDanone drops following report of raised bid for Pfizer unit
Groupe Danone (DANOY) is retreating after the French food maker increased its offer for Pfizer's (PFE) infant nutrition business to close to $11B, according to Reuters, which cited the French website WanSquare. Danone is trying to outbid Nestle (NSRGY), which was nearing a deal for the Pfizer unit last week, Reuters reported, citing unnamed sources. Pfizer's infant nutrition business is growing quickly and is strong in emerging markets, with a key position in China, Reuters added. In late morning trading, Danone dropped 27c, or 1.91%, to $13.89. Pfizer (PFE) is climbing, while Mead Johnson (MJN) and Synutra (SYUT), which also sell infant formula, advanced.
News For DANOY;PFE;MJN;SYUT;NSRGY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 29, 2015
10:39 EDTPFECiti analyst says outlook still strong for big pharma
Subscribe for More Information
10:00 EDTPFEOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Capital Agency (AGNC) downgraded at UBS... American Public Education (APEI) downgraded to Hold from Buy at Deutsche Bank... Annaly Capital (NLY) downgraded at UBS... C.H. Robinson (CHRW) downgraded to Neutral from Buy at BofA/Merrill... Church & Dwight (CHD) downgraded to Perform from Outperform at Oppenheimer... Cobalt (CIE) downgraded to Hold from Accumulate at Tudor Pickering... Compass Minerals (CMP) downgraded to Neutral from Overweight at JPMorgan... Corning (GLW) downgraded to Sell from Underperform at CLSA... Corporate Office Properties (OFC) downgraded at Stifel... Entergy (ETR) downgraded to Market Perform from Outperform at BMO Capital... First Interstate (FIBK) downgraded to Market Perform from Outperform at Wells Fargo... German American Bancorp (GABC) downgraded to Market Perform at Keefe Bruyette... IGI Laboratories (IG) downgraded to Market Perform from Outperform at Avondale... Lumber Liquidators (LL) downgraded at Longbow... Marvell (MRVL) downgraded at JMP Securities... National Oilwell (NOV) downgraded to Underweight from Equal Weight at Morgan Stanley... Oceaneering (OII) downgraded to Neutral from Buy at Sterne Agee CRT... OpenText (OTEX) downgraded to Sector Performer from Outperformer at CIBC... Parker-Hannifin (PH) downgraded on macro headwinds at Stifel... Pfizer (PFE) downgraded to Neutral from Buy at Citigroup... Procter & Gamble (PG) downgraded to Hold from Buy at Societe Generale... RTI International (RTI) downgraded to Market Perform from Outperform at FBR Capital... Ryder (R) downgraded to Neutral from Buy at Goldman... Stratasys (SSYS) downgraded to Neutral from Buy at Goldman... Targa Resources (TRGP) downgraded to Accumulate from Buy at Global Hunter... Total System (TSS) downgraded to Market Perform from Outperform at Wells Fargo... Twitter (TWTR) downgraded to Equal Weight from Overweight at Barclays... Wynn Resorts (WYNN) downgraded to Neutral at Susquehanna.
06:16 EDTPFEPfizer downgraded to Neutral from Buy at Citigroup
Citigroup analyst Andrew Baum downgraded Pfizer (PFE) to Neutral citing the stock's "strong" relative outperformance this year. Buam prefers prefer Eli Lilly (LLY), which he upgraded this morning to Buy, and Bristol-Myers (BMY) among large-cap U.S. Pharmaceuticals. He keeps a $37 price target for Pfizer shares.
April 28, 2015
12:30 EDTPFEOn The Fly: Top stock stories at midday
Stocks on Wall Street were higher at midday after crossing back and forth across the flat line during morning trading, much like Apple (AAPL) shares, which were searching for direction despite the company's report last night having topped expectations on several measures, including revenue, profits, iPhone unit sales and capital return plans. ECONOMIC EVENTS: In the U.S., the Case Shiller 20-city home price index rebounded 0.93% on a seasonally adjusted basis in February, versus expectations for it to be up 0.7% on a month-over-month basis. The Conference Board's consumer confidence index dropped 6.2 points to 95.2 in April, versus expectations for it to have risen to 102.2. The Richmond Fed manufacturing index rose to -3 in April, versus expectations for a reading of -2. COMPANY NEWS: Shares of Apple were little changed near noon after the company last night reported March quarter earnings and sales well above expectations and boosted its shares buyback program to $140B from $90B and quarterly dividend by 11% to 52c. FBR Capital called the quarter “Picasso-like,” while Brian White at Cantor Fitzgerald upped his price target on shares to $195. Less sanguine are analysts at Pacific Crest, Maxim and Deutsche Bank. Noted investor Carl Icahn said afterward that Apple is "still undervalued and misunderstood" and promised to put out another in-depth report on the company within two weeks... IBM (IBM) approved an 18% increase in its quarterly dividend to $1.30 per common share. MAJOR MOVERS: Among the notable gainers was Dow member Merck (MRK), which advanced 5% after its Q1 sales and EPS beat expectations. Two other big name, big revenue drugmakers slid after their earnings reports, as Bristol-Myers (BMY) declined 1% and Pfizer (PFE) fell 0.5%. Also lower following its earnings report was The Container Store (TCS), which declined about 16% after its results and outlook missed expectations. INDEXES: Near midday, the Dow was up 49.61, or 0.28%, to 18,087.58, the Nasdaq was up 9.87, or 0.2%, to 5,070.12, and the S&P 500 was up 3.98, or 0.19%, to 2,112.90.
07:43 EDTNSRGY, MJNMead Johnson pushing for changes to WIC program, WSJ reports
The law authorizing the $6B per year WIC program providing food vouchers to women who are pregnant or have young children is up for renewal this year and formula makers, led by top U.S. maker Mead Johnson (MJN), are pushing for change, said The Wall Street Journal. Growth in the program has made it a money-losing venture for baby formula makers who essentially make no profit off formula sold to states as part of the program and Mead Johnson is pushing for changing eligibility requirements, thereby limiting or even shrinking the pool of recipients, the report noted. Other U.S. infant formula makers include Abbott (ABT) and Nestle (NSRGY). Reference Link
07:33 EDTPFEHospira will not provide annual projections given merger agreement with Pfizer
07:33 EDTPFEHospira expects merger agreement with Pfizer to be completed in 2H15
Subscribe for More Information
07:12 EDTPFEPfizer lowers FY15 adjusted EPS view to $1.95-$2.05 from $2.00-$2.10
Consensus $2.07. Lowers FY15 revenue guidance to $44B-$46B from $44.5B-$46.5B, consensus $45.94B.
07:09 EDTPFEPfizer reports Q1 adjusted EPS 51c, consensus 49c
Subscribe for More Information
April 27, 2015
15:04 EDTPFENotable companies reporting before tomorrow's open
Subscribe for More Information
14:41 EDTPFEEarnings Watch: Pfizer up over 6% since its last earnings report
Subscribe for More Information
12:47 EDTPFEPfizer technical comments before earnings
Subscribe for More Information
09:03 EDTPFEChina Jo-Jo Drugstore signs incentive agreement with Pfizer subsidiary
China Jo-Jo Drugstores (CJJD) announced its subsidiary, Hangzhou Jiuzhou Grand Pharmacy Chain, has signed a new sales incentive agreement with Wyeth Pharmaceutical, a wholly owned subsidiary in China of Pfizer (PFE). The Agreement illustrated specific approaches and conditions of Jiuzhou Pharmacy's collaboration with Wyeth, including sales targets, promotional incentive to consumers, products and pricing methods. In return, Wyeth will fully support Jiuzhou Pharmacy with priority delivery, favorable purchase prices and promotional activities.
08:41 EDTPFETelegraph discusses potential takeover of GSK by Pfizer
Subscribe for More Information
06:19 EDTPFEPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 23, 2015
12:35 EDTDANOYEarnings Watch: Starbucks sees Q2 EPS 32c-33c on split-adjusted basis
Starbucks (SBUX) is scheduled to report second quarter results after the market close on Thursday, April 23, with a conference call scheduled for 5:00 pm ET. Starbucks purchases and roasts whole bean coffees and sells them, along with brewed coffees, Italian-style espresso beverages, cold blended beverages, food items, teas, and beverage-related accessories and equipment, primarily through company-operated retail stores. EXPECTATIONS: Analysts are looking for earnings per share of 33c on revenue of $4.53B, according to First Call. The consensus range for EPS is 31c-35c on revenue of $4.39B-$4.6B. LAST QUARTER: Starbucks reported first quarter EPS of 80c on revenue of $4.8B, in-line with analysts' estimates, respectively. Starbucks said global comparable store sales increased 5%, with a 2% increase in traffic. The company said comparable store transactions increased by nearly 9M in the U.S. and nearly 12M globally, year-over-year. In conjunction with its earnings release, Starbucks announced the appointment of Kevin Johnson as president and Chief Operating Officer. NEWS: At the company's Annual Meeting of Shareholders in March, the company announced a two-for-one stock split. On a split-adjusted basis, the company revised its Q2 EPS view to 32c-33c to account for the planned stock split; previous Q2 EPS guidance was 64c-65c. The company also revised its EPS guidance for fiscal year 2015 to $1.55-$1.57, which compares to analysts' estimates of $1.57; the company's pre-split FY15 EPS view was $3.09-$3.13. At the meeting, Starbucks announced two delivery models, including a collaboration with Postmates, which will allow customers to order their food and beverage items via the Starbucks mobile app, and a "Green Apron" barista delivery option enabling customers within specified office-buildings to order food and beverages for delivery. Starbucks also reaffirmed its goal to grow its market capitalization to $100B and announced an agreement with Chinese food and beverage producer Tingyi Holding to manufacture and expand the distribution of Starbucks ready-to-drink products throughout mainland China. During the quarter, Evolution Fresh, a unit of Starbucks, and Dannon (DANOY) said they would launch co-branded yogurt products. They said they planned to launch Evolution Fresh Smoothies in 4,300 Starbucks stores in the Pacific Northwest, Northern California and in select Starbucks locations within grocery stores nationwide. Starbucks raised suspicions among European regulators and local governments by reporting losses despite hundreds of millions of dollars in annual sales, The Wall Street Journal reported in early April. STREET RESEARCH: BMO Capital recently initiated Starbucks with an Outperform rating, citing what it sees as the company's many growth opportunities. Shares were also recently initiated at Guggenheim with a Buy rating and $56 target and with an Outperform rating and $56 target at Cowen. Goldman said Starbucks is its top pick in the sector and expects an in-line earnings report. Additionally, the firm expects Starbucks to comment on mobile ordering and the potential for traffic acceleration in the back half of the year and into 2016. Piper Jaffray raised its split-adjusted price target for shares of Starbucks to $55 from $53, which implies 16% upside from current levels. Piper's five-year model suggests the company's earnings double. The firm has an Overweight rating on the stock. Bernstein increased its price target on Starbucks as the firm estimates that falling coffee prices will add at least 3c-4c to the company's fiscal 2016 EPS. PRICE ACTION: Ahead of Thursday afternoon's earnings report, shares are up about 1.2% to $48.93.
07:32 EDTMJNMead Johnson reiterates FY15 adjusted EPS view $3.90-$4.00, consensus $4.00
Subscribe for More Information
07:32 EDTMJNMead Johnson reaffirms FY15 non-GAAP guidance
Subscribe for More Information
07:32 EDTMJNMead Johnson reports Q1 adjusted EPS $1.09, consensus $1.05
Subscribe for More Information
April 22, 2015
15:50 EDTMJNNotable companies reporting before tomorrow's open
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use